There are currently 979 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Product Surveillance Registry
NCT01524276
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
ALL
Ages:
All
Trial Updated:
07/24/2025
Locations: Not set, San Antonio, Texas
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Register for Updates
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Texas Oncology-San Antonio Medical Center, San Antonio, Texas
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Register for Updates
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030
Recruiting
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2). Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Colorectal Cancer
Register for Updates
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371
Recruiting
The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/24/2025
Locations: Endeavor Clinical Trials, San Antonio, Texas
Conditions: Asthma
Register for Updates
Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)
NCT06672510
Recruiting
This study is a prospective, single-arm, interventional, multicenter study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Methodist San Antonio (HCA), San Antonio, Texas
Conditions: Pulmonary Embolism Acute
Register for Updates
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010
Recruiting
This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Exelixis Clinical Site #2, San Antonio, Texas
Conditions: Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Register for Updates
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043
Recruiting
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/24/2025
Locations: Climb Bio Investigative Site #100101, San Antonio, Texas
Conditions: Systemic Lupus Erythematosus
Register for Updates
Prostate Active Surveillance Study
NCT00756665
Recruiting
The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.
Gender:
MALE
Ages:
21 years and above
Trial Updated:
07/23/2025
Locations: University of Texas Health Science Center, San Antonio, San Antonio, Texas
Conditions: Prostatic Neoplasms
Register for Updates
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
NCT05411198
Recruiting
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 pa... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/23/2025
Locations: Eye associates /ID# 227572, San Antonio, Texas
Conditions: Open-Angle Glaucoma
Register for Updates
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663
Recruiting
This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD19 and CD20, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Texas Transplant Institute, San Antonio, Texas
Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Register for Updates
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
NCT05479812
Recruiting
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Register for Updates
QTX3034 in Patients With KRAS G12D Mutation
NCT06227377
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: START San Antonio, LLC, San Antonio, Texas
Conditions: Solid Tumors
Register for Updates